Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, January 27th.
Zacks.com on MSN21h
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged at ...
China Universal Asset Management Co. Ltd. grew its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 10.4% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback